A Randomized, Single-Blind, Placebo-Controlled, 3-Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects

scientific article published on 15 June 2020

A Randomized, Single-Blind, Placebo-Controlled, 3-Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/CPDD.814
P932PMC publication ID7818234
P698PubMed publication ID32543120

P2093author name stringShinsuke Inoue
Kazuoki Kondo
Makoto Akimoto
Kaori Yoshida
Yoshinobu Nakamaru
Hidetoshi Shimizu
Masae Kakubari
Mai Endo
Tomoko Natori
P2860cites workTreatment of acute ischemic stroke: recent progressQ28193177
Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimenQ38153555
Operational Characteristics of Linear Concentration-QT Models for Assessing QTc Interval in the Thorough QT and Phase I Clinical Studies.Q39945478
Rate-corrected QT interval: techniques and limitationsQ40788117
Scientific white paper on concentration-QTc modelingQ47361141
A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studiesQ47782666
Edaravone and its clinical development for amyotrophic lateral sclerosisQ47782687
Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populationsQ48033726
Enabling robust assessment of QTc prolongation in early phase clinical trialsQ48324795
Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosisQ50222465
Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosisQ50222468
Bioavailability of Edaravone Sublingual Tablet Versus Intravenous Infusion in Healthy Male VolunteersQ57155471
Beat-to-beat QT dynamics in healthy subjectsQ75291873
Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis TherapeuticsQ88437167
Edaravone: a new hope for deadly amyotrophic lateral sclerosisQ89583589
Edaravone for the treatment of amyotrophic lateral sclerosisQ91955956
P577publication date2020-06-15
P1433published inClinical pharmacology in drug developmentQ27726600
P1476titleA Randomized, Single-Blind, Placebo-Controlled, 3-Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects

Search more.